TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4667-4672

  Wang, Fuxia ^a,b   Fu, Ping ^a   Pang, Yixin ^c   Liu, Chengxiang ^a   Shao, Zhulin ^a   Zhu, Jingyan ^d   Li, Jie ^e   Wang, Ti ^c   Zhang, Xia ^b   Liu, Jie ^a,b  

^a UNIVERSITY OF JINAN   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c People's Hospital of Sishui   (China)

^d Traditional Chinese Medicine Hospital of Weifang   (China)

^e Jining No1 People's Hospital   (China)

Author keywords

Interleukin 6; Lung adenocarcinoma; Polymorphism; TERT

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; TELOMERASE REVERSE TRANSCRIPTASE; IL6 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; VERY ELDERLY; ADENOCARCINOMA; BLOOD; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TELOMERASE; UP-REGULATION;

EID: 84902952824     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1611-z     Document Type: Article

References (25)

1. Chen W, Zhang S, Zou X. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thorac Cancer. 2010;1:35-40.
2. Ding D, Zhou J, Wang M, Cong YS. Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. FEBS J. 2013;280:3205-11.
3. Kirkpatrick KL, Newbold RF, Mokbel K. The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. J Carcinog. 2004;3:1.
4. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003;22:131-46. (Pubitemid 36152891)
5. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol. 2003;5:474-9. (Pubitemid 36592272)
6. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012;14:1270-81.
7. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460:66-72.
8. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H, et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci. 2008;121:1046-53. (Pubitemid 351639423)
9. Haendeler J, Dröse S, Büchner N, Jakob S, Altschmied J, Goy C, et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol. 2009;29:929-35.
10. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008;27:3754-60. (Pubitemid 351912970)
11. Massard C, Zermati Y, Pauleau AL, Larochette N, Métivier D, Sabatier L, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. 2006;25:4505-14. (Pubitemid 44175110)
12. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005;102:8222-7. (Pubitemid 40800070)
13. Perrault SD, Hornsby PJ, Betts DH. Global gene expression response to telomerase in bovine adrenocortical cells. Biochem Biophys Res Commun. 2005;335:925-36. (Pubitemid 41188284)
14. Pande M, Spitz MR, Wu X, Gorlov IP, Chen WV, Amos CI. Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis. 2011;32:1493-9.
15. Lan Q, Cawthon R, Gao Y, Hu W, Hosgood 3rd HD, Barone-Adesi F, et al. Longer telomere length in peripheral white blood cells is associated with risk of lung cancer and the rs2736100 (CLPTM1L-TERT) polymorphismin a prospective cohort study among women in China. PLos One. 2013;8(3):E59230.
16. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene. 1999;232:97-106. (Pubitemid 29305322)
17. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15. 33 and 6p21. 33 variants influence lung cancer risk. Nat Genet. 2008;40:1407.
18. Broderick P, Wang Y, Vijayakrishnan J, Matakidou A, Spitz MR, Eisen T, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009;69:6633.
19. Hsiung CA, Lan Q, Hong YC, Chen CJ, Hosgood III HD, Chang IS, et al. The 5p15. 33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet. 2010;6:e1001051.
20. Myneni AA, Chang SC, Niu R, Liu L, Ochs-Balcom HM, Li Y, et al. Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer - a case-control study in a Chinese population. Lung Cancer. 2013;80:131-7.
21. Jin G, Xu L, Shu Y, Tian T, Liang J, Xu Y, et al. Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis. 2009;30:987-90.
22. Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8:1248-53.
23. Culig Z. Interleukin-6 as a therapy target in oral squamous carcinoma. Expert Opin Ther Targets. 2013;17:53-9.
24. Coward JI, Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev. 2012;23:333-42.
25. Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, et al. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res. 2012;32:3251-8.